Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL, 19-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives, announced that their combination treatment … Read the full press release
Annonce ad hoc conformément à l’art. 53LR (COMMUNIQUÉ DE PRESSE) BÂLE, 19-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), un pionnier mondial des produits pharmaceutiques et des diagnostics axé sur l’avancement de la science pour améliorer la vie des … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged atezolizuma, Avastin®, bevacizumab, cancer du foie, Cancer Immunotherapy, carcinome hépatocellulaire à un stade précoce, CHC, early-stage hepatocellular carcinoma, étude IMbrave050, HCC, IMbrave050 study, immunothérapie anticancéreuse, Levi Garraway M.D. Ph.D., liver cancer, Roche, Tecentriq®
New test featured today in Gut, a leading international journal published by BMJ, uses A.I. to accurately predict the stages of the whole spectrum of liver diseases, from NAFLD to NASH and liver fibrosis (PRESS RELEASE) BOSTON, MA, United States, … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Technology
Tagged A.I., blood test, BMJ, cirrhosis, diagnosis, Frank Jaksch, gastroenterology journal, gut, HEPAR-QTM, hepatology journal, King’s College London, liquid biopsy, liquid biopsy test, liver biopsy, liver cancer, liver diseases, liver fibrosis, metabolic diseases diagnostics, Metadeq, NAFLD, NASH, NASH Diagnosis Problem, non-alcoholic fatty liver disease, Non-alcoholic steato-hepatitis, Non-Invasive Blood Test, novel protein biomarkers, PLIN2, predictive algorithm, Professor Geltrude Mingrone, RAB14, SDDPR, Stacey Doss
Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III study programme includes treatment naïve patients, including those ineligible for interferon and patients with liver cirrhosis The milestone coincides with … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged BI 207127, blood-borne infectious disease, Boehringer Ingelheim, Boehringer Ingelheim hepatitis C clinical trials, Dr Reinhard Malin, genoytpe-1 HCV, HCVerso™, HCVerso™ trials, hepatitis C clinical trials, hepatitis C virus, hronic liver disease, liver cancer, Phase IIb interferon-free SOUND-C2 study, Phase IIb SOUND-C3 study, pivotal Phase III HCVerso™1 and 2 trials, Professor Klaus Dugi, protease inhibitor faldaprevir, sustained virological response
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
